Cargando…

Compounded non-FDA–approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey

OBJECTIVE: From a survey of compounding pharmacists, specific questions regarding compounded menopausal hormone therapy were used to estimate compounded hormone therapy (CHT) prescribing in the United States. METHODS: A national online survey was conducted by Rose Research—a market research company...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinkerton, JoAnn V., Constantine, Ginger D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott-Raven Publishers 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819678/ https://www.ncbi.nlm.nih.gov/pubmed/26645819 http://dx.doi.org/10.1097/GME.0000000000000567

Ejemplares similares

Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy
por: Pinkerton, JoAnn V., et al.
Publicado: (2016)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women
por: Pinkerton, JoAnn V., et al.
Publicado: (2015)

The availability of gonadotropin therapy from FDA-approved pharmacies for men with hypogonadism and infertility
por: Borgert, Benjamin J, et al.
Publicado: (2023)

Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval
por: Shaw, Daniel L., et al.
Publicado: (2018)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
por: Panic, Gordana, et al.
Publicado: (2015)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts
por: Mehta, Jaya, et al.
Publicado: (2021)

Screening of an FDA-approved compound library identifies apigenin for the treatment of myocardial injury
por: Li, Haixia, et al.
Publicado: (2023)

A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause
por: Madsen, Tracy E, et al.
Publicado: (2023)

A Detailed Analysis of the Past 20 Years of US FDA-Approved Prescription to Over-the-Counter Switches
por: Fisher, Matt, et al.
Publicado: (2023)

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence
por: Archer, David F., et al.
Publicado: (2015)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Does publication bias explain the divergent findings on menopausal hormone therapy and cardioprotection in the literature?
por: El Khoudary, Samar R., et al.
Publicado: (2021)

Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause
por: Pinkerton, JoAnn V., et al.
Publicado: (2015)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

Use of surrogate outcomes in US FDA drug approvals, 2003–2012: a survey
por: Yu, Tsung, et al.
Publicado: (2015)

Update to Drugs, Devices, and the FDA: How Recent Legislative Changes Have Impacted Approval of New Therapies
por: Van Norman, Gail A.
Publicado: (2020)

Changes of the prescription of hormone therapy in menopausal women: An observational study in Taiwan
por: Huang, Weng-Foung, et al.
Publicado: (2007)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7m230s299i81ckaipebt98q9g4